Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Multi targeting agents are of major interest in modern
2022-10-10

Multi-targeting agents are of major interest in modern drug design and discovery. Design of such compounds can be applied to H3R antagonists for the purpose of achieving optimum efficiency as performed for some preclinical candidates such as recently for contilisant (Bautista-Aguilera et al., 2017;
-
The overall response rate to afatinib is comparable to
2022-10-10

The 13% overall response rate to afatinib is comparable to a 19% response rate reported by Peters et al. [20] in a separate retrospective series investigating the use of afatinib in more heavily pretreated patients with HER2-mutant lung adenocarcinomas. Our 13% response rate is also comparable to an
-
We acknowledge some important limitations to
2022-10-10

We acknowledge some important limitations to the study. Given that SEER is a national database of abstracted clinical information, there is selection bias as to which patients underwent RS testing. As clinicians are selecting which patients to test, the RS distributions may not reflect the true dist
-
Treatment and control for IBD are targeted to
2022-10-10

Treatment and control for IBD are targeted to identify and eliminate the cause if possible, decrease intestinal inflammation, reduce diarrhea and vomiting, improve appetite, and promote weight gain. Methods include dietary manipulation with or without concurrent medical therapy such as corticosteroi
-
Treatment and control for IBD are targeted to
2022-10-10

Treatment and control for IBD are targeted to identify and eliminate the cause if possible, decrease intestinal inflammation, reduce diarrhea and vomiting, improve appetite, and promote weight gain. Methods include dietary manipulation with or without concurrent medical therapy such as corticosteroi
-
There are several limitations in
2022-10-10

There are several limitations in our study. First, only the naturally occurring resistance-associated mutations in patients coinfected with HIV/HCV Lopinavir receptor 1b were analyzed. The result was only applicable to HCV genotype 1b, but not the HCV genotype 1a patients. We did not analyze the ef
-
br Experimental br Acknowledgment br Introduction Hepatitis
2022-10-10

Experimental Acknowledgment Introduction Hepatitis C virus (HCV) belongs to Flaviviridae, is a blood-borne pathogen which infects about 180 million individuals throughout the world; most of the cases lead to end stage liver diseases, fibrosis, cirrhosis and hepatocellular carcinoma (Choo et
-
Aurora kinase B AURKB and haploid cell
2022-10-10

Aurora kinase B (AURKB) and haploid cell-specific protein kinase (Haspin) are two well-known participants in N-terminal histone H3 phosphorylations during mitosis. A related role played by these kinases relates to the fact that AURKB is activated by Haspin promoted phosphorylation at T3. Irrespectiv
-
br Introduction The signaling molecule nitric oxide NO
2022-10-10

Introduction The signaling molecule nitric oxide (NO) plays an essential role in vessel homeostasis by initiating vasodilation [1], [2], [3]. After biosynthesis in endothelial cells, NO diffuses into the subjacent smooth muscle layer to reach its target enzyme, soluble guanylyl cyclase (sGC, EC 4
-
Screening of the compounds allowed for a number of
2022-10-10

Screening of the compounds allowed for a number of interesting SAR observations. First of all, pyridyl analogue demonstrated that a pyridine ring would be beneficial for both log as well as increasing the potency (entry 2 versus entry 1). Electron-poor aryl groups next to the oxadiazolone were detr
-
In this study with the use of C
2022-10-09

In this study, with the use of 13C515N2-labeled glutamine, we observed that 13C515N2-labeled glutamine produces a wide range of NAAG isotopologues and its precursors: NAA and glutamate. The NAAG production from glutamine is consistently more elevated in MYC-ON lymphoma and OVCAR4 compared to MYC-OFF
-
As a part of our continuing efforts towards discovery of
2022-10-09

As a part of our continuing efforts towards discovery of new class of compounds against different therapeutic areas and based on the literature reports, we designed a dual pharmacophore which possess a long aliphatic chain of free fatty acids and a phenyl propanoid part of known GPR40 agonists. Here
-
ICH induced striatal lesion produced a
2022-10-09

ICH-induced striatal lesion produced a reduction of EAAT1 expression analogous to the decreased glutamate uptake at 6 h. The combined reduction of excitatory amino Tacalcitol transporters and of glutamate uptake activity might explain the well-known glutamate excitotoxicity following brain ischemia
-
ICH induced striatal lesion produced a
2022-10-09

ICH-induced striatal lesion produced a reduction of EAAT1 expression analogous to the decreased glutamate uptake at 6 h. The combined reduction of excitatory amino Tacalcitol transporters and of glutamate uptake activity might explain the well-known glutamate excitotoxicity following brain ischemia
-
ICH induced striatal lesion produced a
2022-10-09

ICH-induced striatal lesion produced a reduction of EAAT1 expression analogous to the decreased glutamate uptake at 6 h. The combined reduction of excitatory amino Tacalcitol transporters and of glutamate uptake activity might explain the well-known glutamate excitotoxicity following brain ischemia
15788 records 389/1053 page Previous Next First page 上5页 386387388389390 下5页 Last page